Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing

Genome Biology

Volumn 17, Issue 1, 2016, Pages

  Demeulemeester, Jonas ^a,b   Kumar, Parveen ^b,c   Møller, Elen K ^d   Nord, Silje ^d   Wedge, David C ^c   Peterson, April ^e,f   Mathiesen, Randi R ^d,g   Fjelldal, Renathe ^d   Zamani Esteki, Masoud ^b   Theunis, Koen ^b   Fernandez Gallardo, Elia ^b   Grundstad, A Jason ^e   Borgen, Elin ^d   Baumbusch, Lars O ^d   Børresen Dale, Anne Lise ^d   White, Kevin P ^e,i   Kristensen, Vessela N ^d,g   Van Loo, Peter ^a,b   Voet, Thierry ^b,c   Naume, Bjørn ^d,h  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ Tempus Labs Inc   (United States)

Author keywords

Disseminated tumor cells; Intra tumor genetic heterogeneity; Metastasis; Phylogeny; Single cell sequencing

Indexed keywords

AXILLARY LYMPH NODE METASTASIS; BONE MARROW BIOPSY; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DOSAGE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MOLECULAR CLONING; REVIEW; SINGLE CELL ANALYSIS; SINGLE CELL SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; AMINO ACID SUBSTITUTION; AXILLA; BONE MARROW CELL; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COPY NUMBER VARIATION; DNA SEQUENCE; GENETICS; IMMUNOHISTOCHEMISTRY; LYMPH NODE; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; TUMOR EMBOLISM; VERY ELDERLY;

TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; AXILLA; BIOMARKERS, TUMOR; BONE MARROW CELLS; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; SEQUENCE ANALYSIS, DNA; SINGLE-CELL ANALYSIS;

EID: 85002640264     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-016-1109-7     Document Type: Review

References (49)

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719-24.
2. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13:795-806.
3. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666-77.
4. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, et al. The life history of 21 breast cancers. Cell. 2012;149:994-1007.
5. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395-9.
6. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90-4.
7. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155-60.
8. Barber LJ, Davies MN, Gerlinger M. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev. 2014;30C:1-6.
9. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834-46.
10. Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X, Li F, Wu K, Liang J, Shao D, et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell. 2012;148:873-85.
11. Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012;148:886-95.
12. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DYR, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15:807-17.
13. Banys M, Krawczyk N, Fehm T. The role and clinical relevance of disseminated tumor cells in breast cancer. Cancers (Basel). 2014;6:143-52.
14. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793-802.
15. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525-33.
16. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, Sommer H, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res. 2011;17:2967-76.
17. Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, Janbu J, Harbitz T, Nesland JM. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res. 2004;10:3091-7.
18. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21:3469-78.
19. Mathiesen RR, Borgen E, Renolen A, Lokkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res. 2012;14:R117.
20. Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Kramer B, Vogel U, Neubauer H, Wallwiener D, Huober J, Fehm TN. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat. 2006;98:179-84.
21. Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14:611-22.
22. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9:302-12.
23. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100:7737-42.
24. Gangnus R, Langer S, Breit E, Pantel K, Speicher MR. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res. 2004;10:3457-64.
25. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmuller G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002;360:683-9.
26. Mathiesen RR, Fjelldal R, Liestol K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, et al. High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer. 2012;131:E405-15.
27. Czyz ZT, Hoffmann M, Schlimok G, Polzer B, Klein CA. Reliable single cell array CGH for clinical samples. PLoS One. 2014;9, e85907.
28. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer. 2006;107:885-92.
29. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy. 1999;1:377-88.
30. Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome. Breast Cancer Res Treat. 2013;138:485-97.
31. Navin NE. The first five years of single-cell cancer genomics and beyond. Genome Res. 2015;25:1499-507.
32. Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, Schlichting E, Qvist H, Naume B. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol. 1998;185:427-34.
33. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009;27:1549-56.
34. Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013;501:365-72.
35. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275-92.
36. Knouse KA, Wu J, Whittaker CA, Amon A. Single cell sequencing reveals low levels of aneuploidy across mammalian tissues. Proc Natl Acad Sci U S A. 2014;111:13409-14.
37. Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, Zhang H, et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016;48:1119-30.
38. Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, Hutchinson A, Deng X, Liu C, Horner MJ, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44:651-8.
39. Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, Ling H, Hetrick KN, Pugh EW, Amos C, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44:642-50.
40. Moller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, et al. Next-generation sequencing of disseminated tumor cells. Front Oncol. 2013;3:320.
41. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A. 2010;107:16910-5.
42. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011;1:457-70.
43. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061-73.
44. Nilsen G, Liestol K, Van Loo P, Moen Vollan HK, Eide MB, Rueda OM, Chin SF, Russell R, Baumbusch LO, Caldas C, et al. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics. 2012;13:591.
45. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-60.
46. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213-9.
47. Ardeshirdavani A, Souche E, Dehaspe L, Van Houdt J, Vermeesch JR, Moreau Y. NGS-Logistics: federated analysis of NGS sequence variants across multiple locations. Genome Med. 2014;6:71.
48. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29:24-6.
49. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297-303.